[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601785":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":175,"collaborators":20,"id":177,"slug":20,"hasResults":178,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":178,"sex":184,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":20,"studyType":190,"phases":191,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},{"fullName":5,"class":6},"Vega Therapeutics, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multiple Doses of VGA039 after observational run-in","EXPERIMENTAL","Participants who meet eligibility criteria and complete a 24-week observational phase will receive VGA039 SC for approximately 49 weeks.",[13],"Drug: VGA039",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","VGA039","VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Clinical Trials- Vega Therapeutics","CONTACT","650-466-8041","medinfo@star-therapeutics.com",[28,41,51,60,69,82,88,98,113,123,133,146,155,165],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"Arkansas Children's Hospital","RECRUITING","Little Rock","Arkansas","72202","United States",{"type":36,"coordinates":37},"Point",[38,39],-92.28959,34.74648,{"lat":39,"lon":38},{"facility":42,"status":30,"city":43,"state":44,"zip":45,"country":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":20},"Luskin Orthopaedic Institute For Children","Los Angeles","California","90007",{"type":36,"coordinates":47},[48,49],-118.24368,34.05223,{"lat":49,"lon":48},{"facility":52,"status":30,"city":53,"state":44,"zip":54,"country":34,"cosmosGeoPoint":55,"geoPoint":59,"contacts":20},"UC Davis Medical Center","Sacramento","95817",{"type":36,"coordinates":56},[57,58],-121.4944,38.58157,{"lat":58,"lon":57},{"facility":61,"status":30,"city":62,"state":44,"zip":63,"country":34,"cosmosGeoPoint":64,"geoPoint":68,"contacts":20},"University of California San Francisco","San Francisco","94143",{"type":36,"coordinates":65},[66,67],-122.41942,37.77493,{"lat":67,"lon":66},{"facility":70,"status":30,"city":71,"state":72,"zip":73,"country":34,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Emory University Hospital","Atlanta","Georgia","30308",{"type":36,"coordinates":75},[76,77],-84.38798,33.749,{"lat":77,"lon":76},[80],{"name":70,"role":24,"phone":81,"phoneExt":20,"email":20},"(404) 686-0277",{"facility":83,"status":30,"city":71,"state":72,"zip":84,"country":34,"cosmosGeoPoint":85,"geoPoint":87,"contacts":20},"Children's Healthcare of Atlanta","30329",{"type":36,"coordinates":86},[76,77],{"lat":77,"lon":76},{"facility":89,"status":30,"city":90,"state":91,"zip":92,"country":34,"cosmosGeoPoint":93,"geoPoint":97,"contacts":20},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":36,"coordinates":94},[95,96],-93.26384,44.97997,{"lat":96,"lon":95},{"facility":99,"status":30,"city":100,"state":101,"zip":102,"country":34,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Science 37, Inc. (Virtual Clinical MetaSite)","Morrisville","North Carolina","27560",{"type":36,"coordinates":104},[105,106],-78.82556,35.82348,{"lat":106,"lon":105},[109],{"name":110,"role":24,"phone":111,"phoneExt":20,"email":112},"Science 37 Recruitment Team","1-855-737-3711","recruitment@science37.com",{"facility":114,"status":30,"city":115,"state":116,"zip":117,"country":34,"cosmosGeoPoint":118,"geoPoint":122,"contacts":20},"Hemophilia Center of Western PA","Pittsburgh","Pennsylvania","15213",{"type":36,"coordinates":119},[120,121],-79.99589,40.44062,{"lat":121,"lon":120},{"facility":124,"status":30,"city":125,"state":126,"zip":127,"country":34,"cosmosGeoPoint":128,"geoPoint":132,"contacts":20},"UT Southwestern Children's Hospital","Dallas","Texas","75235",{"type":36,"coordinates":129},[130,131],-96.80667,32.78306,{"lat":131,"lon":130},{"facility":134,"status":30,"city":135,"state":136,"zip":137,"country":34,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Washington Center for Bleeding Disorders","Seattle","Washington","98101",{"type":36,"coordinates":139},[140,141],-122.33207,47.60621,{"lat":141,"lon":140},[144],{"name":20,"role":24,"phone":20,"phoneExt":20,"email":145},"Research@WACBD.org",{"facility":147,"status":30,"city":148,"state":20,"zip":149,"country":72,"cosmosGeoPoint":150,"geoPoint":154,"contacts":20},"K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)","Tbilisi","0159",{"type":36,"coordinates":151},[152,153],44.83412,41.69143,{"lat":153,"lon":152},{"facility":156,"status":30,"city":157,"state":20,"zip":158,"country":159,"cosmosGeoPoint":160,"geoPoint":164,"contacts":20},"Frankfurt University Hospital (Universitätsmedizin Frankfurt)","Frankfurt","60596","Germany",{"type":36,"coordinates":161},[162,163],10.53333,49.68333,{"lat":163,"lon":162},{"facility":166,"status":30,"city":167,"state":20,"zip":168,"country":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":20},"Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist","Johannesburg","2194","South Africa",{"type":36,"coordinates":171},[172,173],28.04363,-26.20227,{"lat":173,"lon":172},{"type":176,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100601785",false,"NCT07115004","Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)","A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)","VIVID-6","Key Inclusion Criteria\n\n* 12 to 75 years of age, inclusive\n* No clinically significant laboratory, ECG, or vital signs results\n* Documented diagnosis consistent with VWD of any type\n* Historical annualized bleeding rate (ABR; excluding menstrual bleeds and bleeds under the skin) of both untreated and treated bleeds ≥12 per year\n* Patients with VWD who are judged by the investigator to be suitable candidates for routine prophylaxis to reduce the frequency of bleeding episodes\n* Hemoglobin level ≥ 8 g\u002FdL and platelet count ≥ 100 x 109\u002FL at Screening\n\nKey Exclusion Criteria\n\n* Use of routine prophylaxis of VWF-containing concentrates defined as at least 1 VWF-containing concentrate infusion to prevent or reduce bleeding per week during the previous 6 months prior to screening\n* Planning to initiate routine prophylaxis with VWF-containing concentrates or any other hemostatic treatment during the study\n* Patients with pro-thrombotic disorders or abnormal findings on laboratory thrombophilia evaluation performed at screening or previously documented\n* History of arterial or venous thrombosis, including superficial thrombophlebitis, or embolism\n* Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, or metabolic dysfunction\n* Baseline FVIII activity \\> lower limit of normal (LLN)","ALL","12 Years","75 Years",{"count":188,"type":189},60,"ESTIMATED","INTERVENTIONAL",[192],"PHASE3","This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)",[195],"Von Willebrand Disease (VWD)",[197,198,182,199,200,17],"VWD","von Willebrand Disease","Vega Therapeutics","Star Therapeutics","2026-04-02",{"date":203,"type":204},"2026-04-03","ACTUAL",{"date":206,"type":204},"2025-10-15",{"date":208,"type":189},"2028-10",{"name":5,"class":6},14]